Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Commerce

###### Patent and Trademark Office

          - [Docket No. PTO-P-2021-0052]

# AGENCY:

United States Patent and Trademark Office, Department of Commerce.

# ACTION:

Notice of interim patent term extension.

# SUMMARY:

The United States Patent and Trademark Office has issued an order granting a one-year interim extension of the term of U.S. Patent No. 7,199,162 (‘162 patent).

# FOR FURTHER INFORMATION CONTACT:

                        Raul Tamayo, Senior Legal Advisor, Office of Patent Legal Administration, at 571-272-7728 or                         *raul.tamayo@uspto.gov.*

# SUPPLEMENTARY INFORMATION:

35 U.S.C. 156 generally provides that the term of a patent may be extended for a period of up to five years, if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review. 35 U.S.C. 156(d)(5) generally provides that the term of such a patent may be extended for no more than five interim periods of up to one year each, if the approval phase of the regulatory review period (RRP) is reasonably expected to extend beyond the expiration date of the patent.

                    On August 28, 2023, Medac Gesellschaft fuer Klinische Spezialpraparate mbH, the owner of record of the ‘162 patent, timely filed an application under 35 U.S.C. 156(d)(5) for a third interim extension of the term of the ‘162 patent. The ‘162 patent claims a method of using the human drug product known by the tradename GRAFAPEXTM                     (treosulfan). The application for interim patent term extension indicates that a RRP as described in 35 U.S.C. 156(g)(1)(B)(ii) began for GRAFAPEXTM                     (treosulfan) and is ongoing before the Food and Drug Administration for permission to market and use the product commercially.                

                    Review of the interim patent term extension application indicated that, except for permission to market or use the product commercially, the ‘162 patent would be eligible for an extension of the patent term under 35 U.S.C. 156. Because it was apparent that the RRP would continue beyond the twice-extended expiration date of the ‘162 patent,                     *i.e.,*                     October 12, 2023, a third interim extension of the patent term under 35 U.S.C. 156(d)(5) was appropriate.                          ( print page 71534)    

A third interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 7,199,162 was granted on October 10, 2023, for a period of one year from the twice-extended expiration date of the ‘162 patent.

Brian Hanlon,

Acting Deputy Commissioner for Patents, United States Patent and Trademark Office.

[FR Doc. 2023-22836 Filed 10-16-23; 8:45 am]

BILLING CODE 3510-16-P